First human test for new celiac disease detection method
NCT ID NCT07377565
Summary
This early-stage study is testing the safety of a single dose of a new oral diagnostic agent called HB-2121 in adults who are already scheduled for a standard celiac disease scope test. The main goal is to see what side effects participants experience and how the agent interacts with the small intestine. Researchers will closely monitor 20 participants for 30 days after they take the agent.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Stanford Medicine Clinical and Translational Research Unit (CTRU)
Palo Alto, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.